2024 Revenues ($USD) : $14.20B

Regeneron Pharmaceuticals, Inc. posted total revenues of $14.20 billion for the full year 2024, an 8% increase compared to the previous year. The momentum carried through the end of the year, with fourth-quarter revenues hitting $3.79 billion, up 10% from Q4 2023. Under CEO Leonard Schleifer, the company kept its foot on the R&D pedal, investing over $4.4 billion during 2024.

On the news front, Regeneron highlighted several recent regulatory and pipeline milestones. In March 2025, its Dupixent (dupilumab) snagged approval in Japan for chronic obstructive pulmonary disease (copd) – a notable first for a biologic in that indication there. Just before that, in February, the U.S. FDA accepted for Priority Review a supplemental application for Dupixent aimed at bullous pemphigoid.

February was busy, as the European Medicines Agency's CHMP also gave a positive nod, recommending EU approval for linvoseltamab to treat relapsed/refractory multiple myeloma. Stateside, the FDA accepted the application for odronextamab targeting relapsed/refractory follicular lymphoma. Regeneron also shared some positive results from the CHORD trial for DB-OTO, an investigational gene therapy, reporting meaningful hearing improvements in kids with a specific type of genetic hearing loss.

Regeneron continues to emphasize its model of relying on internal science and its VelociSuite tech platform, building out its portfolio and pipeline across immunology, oncology, rare diseases, and ophthalmology.